Alkermes
Logotype for Alkermes plc

Alkermes (ALKS) investor relations material

Alkermes Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Alkermes plc
Jefferies Global Healthcare Conference summary18 Nov, 2026

Pipeline progress and upcoming catalysts

  • Positive ALKS 2680 NT2 data advanced the program to Phase III; positive LUMRYZ idiopathic hypersomnia results support registration progress; positive ADHD data from orexin agonist ALKS 7290 led to clinical entry.

  • Roughly six trial readouts were expected over the 12 months through the end of the following year, including the idiopathic hypersomnia study at year-end, three Phase III programs around midyear, ADHD Phase II dose-ranging in early fall and ALKS 4510 fatigue after that.

Orexin agonism beyond hypersomnolence

  • Development beyond hypersomnolence is guided by neurotransmitter-release and pharmacology research; ADHD and MDD were identified as neuroscience areas with translational potential and a focus on probability of success and return on investment.

  • In MDD research, orexin agonism showed synergistic serotonin release in the prefrontal cortex and other brain areas when combined with SSRIs or SNRIs; the approach is intended to address depression biology rather than sleep symptoms alone.

  • NT1 and NT2 studies showed dose-responsive cognitive improvement, moving patients from moderate or severe cognitive deficits to normal; further clinical work is needed to establish a separate cognitive claim.

  • Maintenance data showed continued improvement with prolonged use and benefit after dose optimization; dose and duration effects will be important design considerations in ADHD and MDD studies.

Idiopathic hypersomnia and dosing

  • IH patients were characterized as heterogeneous and similar to NT2 patients, with intact orexin tone and expected similar effect size; long sleepers also experience excessive daytime sleepiness, while the Phase III study will quantify efficacy.

  • A placebo-adjusted 2–3-point ESS change was described as clinically meaningful; unmet need is substantial, and oxybates are not suitable for every patient.

  • NT2 maintenance data showed a spectrum of response, with patients at different dose levels normalizing over time; a subset had lower afternoon MWT performance, prompting split dosing across programs.

  • The upcoming clinical study will provide the first split-dose performance results in a maintenance setting.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Alkermes earnings date

Logotype for Alkermes plc
Q4 202624 Feb, 2027
Alkermes
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Alkermes earnings date

Logotype for Alkermes plc
Q4 202624 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Alkermes plc is a biopharmaceutical company engaged in the development, manufacturing, and commercialization of innovative medicines. The company focuses on therapies for central nervous system disorders, including schizophrenia, bipolar disorder, and addiction, as well as treatments for other chronic diseases. Alkermes serves the healthcare sector by advancing solutions that address unmet medical needs. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.